DermNexus 2026 Day 1: Nonsteroidal Topicals, Shared Immune Pathways, and HS Burden

DermNexus 2026 opened on November 21 with a focus on emerging nonsteroidal topical therapies, shared immune pathways in autoimmune skin conditions, and the hidden patient burdens of hidradenitis suppurativa, as Dermatology Times reported.

The morning program at the meeting examined nonsteroidal topical treatments including JAK inhibitors, phosphodiesterase 4 inhibitors, and aryl hydrocarbon receptor agonists. Faculty reviewed ruxolitinib and delgocitinib as topical JAK inhibitors, alongside crisaborole, roflumilast, and difamilast for PDE4 inhibition, while highlighting tapinarof as an AhR agonist that modulates inflammatory signaling and supports skin-barrier protein expression.

Treatment selection across these classes requires looking beyond disease severity to weigh anatomical location, tolerability, and patient preferences. A continuing education symposium titled “Pediatric Atopic Dermatitis: Role of Advanced Topical Therapies in Optimizing Management” addressed the specific challenges that chronic inflammation and pruritus present for young patients and their caregivers.

  • Targeted nonsteroids: Newer topical therapies like JAK and PDE4 inhibitors target specific immune pathways without the long-term side effect profile of traditional steroids.
  • Individualized care: Choosing a treatment depends heavily on patient age, where the rash appears on the body, and individual tolerance.
  • Cross-condition connections: Conditions that look different on the surface, such as vitiligo and alopecia areata, often share underlying immune drivers.

The afternoon educational program transitioned to “Cross Talk: Immune Pathways in Vitiligo & Alopecia Areata,” focusing on immunologic connections between the two autoimmune conditions. In vitiligo, interferon gamma–associated signaling drives responses against melanocytes, whereas alopecia areata involves cytotoxic T cells and cytokine signaling causing hair follicle dysfunction. These shared mechanisms have spurred clinical interest in JAK inhibition for both diseases, pointing toward broader therapeutic opportunities across distinct clinical presentations.

Later in the day, the session “Hidden Disease: Recognizing, Treating & Supporting Patients with HS” examined hidradenitis suppurativa, a chronic condition marked by recurrent inflammatory nodules, abscesses, and scarring in intertriginous areas. The session showed how the disease affects pain, mobility, and psychosocial well-being, demanding comprehensive management strategies that factor in structural damage and patient-reported outcomes.

Non-continuing education product theaters also addressed the IL-31 neuroimmune pathway and treatment options for moderate to severe atopic dermatitis during the 90-minute PODS session ending the day. The meeting continues on November 21 with sessions exploring rheumatologic connections, gastrointestinal warning signs, and the psychological burden of chronic skin disease.

Therapeutic Class Examples Mechanism / Focus
JAK Inhibitors Ruxolitinib, delgocitinib Intracellular cytokine signaling modulation
PDE4 Inhibitors Crisaborole, roflumilast, difamilast Enzyme inhibition to reduce inflammation
AhR Agonists Tapinarof Modulates signaling and supports skin-barrier proteins

The meeting continues November 21 with an expanded focus on the systemic and multidisciplinary dimensions of inflammatory skin disease.

  • Guttman-Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024;191(4):488-496.
  • Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994.
  • Ingram JR, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009-1017. https://doi.org/10.1111/bjd.17537
Photo of author

Health Desk

Health Desk at Archyde.

Millions of Viewers Confronted an Unspoken Family Obligation

North American Police Warn: ‘Play the Game’ Not Reality